PX1 Research Releases USA-Made Retatrutide and Tirzepatide Peptides with 99%+ Purity and Full HPLC Batch Verification

PX1 Research has announced the release of new batches of Retatrutide research peptides and Tirzepatide research peptides, manufactured domestically under current Good Manufacturing Practice (cGMP) standards and verified through rigorous HPLC batch verification protocols. This release marks a significant expansion of the company’s dual-incretin peptide catalog, with every batch now supported by full Certificates of Analysis confirming purity ratings of 99% or above.

The importance of this release lies in the stringent quality assurance measures that underpin it. PX1 Research produces its peptide compounds in USA cGMP-certified facilities, a manufacturing standard that governs facility conditions, equipment qualification, personnel training, and documentation practices. The company draws on over 16 years of peptide manufacturing expertise, a depth of operational history that informs both formulation precision and quality control methodology.

Domestic cGMP manufacturing carries specific compliance implications for research institutions and procurement teams. Facilities operating under these standards are subject to established federal regulatory frameworks, providing a traceable chain of production documentation. For research programs that depend on consistent compound performance across experimental replicates, the source and verification status of a peptide can materially affect data integrity.

Each batch of Retatrutide and Tirzepatide released by PX1 Research undergoes a seven-stage testing protocol prior to shipment. HPLC batch verification—high-performance liquid chromatography—serves as the analytical backbone of this process, separating peptide compounds within a sample to quantify purity with high resolution. The seven-stage framework extends quality assessment beyond chromatographic purity alone, encompassing additional analytical checkpoints designed to detect endotoxin contamination, verify amino acid sequence integrity, and confirm accurate mass through spectrometric analysis. The outcome is a batch-specific Certificate of Analysis that researchers can reference against their own quality requirements before use.

HPLC batch verification is considered a standard methodology in pharmaceutical-grade compound testing, and its application at the batch level—rather than as a periodic or sample-based audit—means that every individual shipment carries documentation reflecting its specific test results rather than generalized lot data. This level of transparency is crucial for research teams that require reproducibility and reliability in their studies.

Both compounds occupy significant positions in current metabolic and endocrine research. Tirzepatide functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Retatrutide extends this mechanism further as a triple agonist, also engaging the glucagon receptor in addition to GIP and GLP-1 pathways. The structural complexity of these molecules places particular demands on manufacturing precision, as minor sequence deviations or degradation products can alter receptor binding profiles. PX1 Research’s positioning of both peptides within the same cGMP manufacturing and verification framework allows research teams to source compounds with comparable documentation standards, a practical consideration for programs comparing the two molecules or running parallel study arms.

The newly released batches are available for procurement through PX1 Research’s catalog, with the Retatrutide offering and the Tirzepatide offering accessible at px1research.com. Certificates of Analysis corresponding to current batch numbers are made available alongside each product listing, ensuring researchers have full access to quality documentation.